Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments

Major limitations of current melanoma treatments are for instances of relapse and the lack of therapeutic options for BRAF wild-type patients who do not respond to immunotherapy. Many studies therefore focus on killing resistant subpopulations, such as Melanoma Initiating Cells (MICs) to prevent rel...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Mukherjee, Nabanita, Almeida, Adam, Partyka, Katie A., Lu, Yan, Schwan, Josianna V., Lambert, Karoline, Rogers, Madison, Robinson, William A, Robinson, Steven E, Applegate, Allison J, Amato, Carol M, Luo, Yuchun, Fujita, Mayumi, Norris, David A., Shellman, Yiqun G.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5356684/
https://ncbi.nlm.nih.gov/pubmed/27829238
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13141
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados